SAN DIEGO,
June 23, 2017
/PRNewswire/ -- CARsgen Therapeutics (CARsgen),
a global biotech start-up focused on developing chimeric antigen
receptor T-cell (CAR-T cell) therapies for solid tumors, presented
at the 2017 BIO International Convention this week in San Diego, CA.
For its progress on cancer immunotherapy, typically for
CAR-T therapies to treat solid tumors, CARsgen Therapeutics was
invited to have a company presentation at the conference. Zonghai
Li, MD, Ph.D., President and CEO of CARsgen, highlighted the
promising efficacy and clinical benefits of leveraging CAR-T
therapy to treat cancer. He also introduced the leading expertise
of the company on CAR-T technology and shared the latest Phase-I clinical
results from GPC3-CAR-T cell trial, a first-in-class clinical trial
initiated by CARsgen to treat refractory/relapsed hepatocellular carcinoma. "I am very glad to
be invited to BIO 2017 to share our updates to bio companies and
professionals within this community. BIO is a great platform for us
to explore more global strategic partnerships to integrate our
expertise to meet the huge unmet medical needs in cancer
treatment."
About BIO International Convention
The BIO International Convention is a global platform
committed to facilitate the development of biotech and biopharm
industry. Hosted by the Biotechnology Innovation
Organization (BIO) since 1993, BIO International
Convention is now the largest bio convention in the world. This
year it has attracted over 16,000 biotechnology and pharma leaders
for one week of intensive networking to discover new opportunities
and promising partnerships.
About CARsgen Therapeutics
CARsgen Therapeutics is a rapidly growing bio-tech
start-up with the original CAR-T therapy discovery expertise,
competitive GMP manufacturing capability, and global clinical
development experience. CARsgen commit to deliver the most advanced
yet affordable cell therapies to patients with unmet medical needs.
With broad discovery pipeline across solid tumor and hematology
malignancies, CARsgen proceeds the clinical development with a
clear focus in CAR-T therapy for solid tumors. Founded in
Nov 2014, CARsgen raised $30M in early 2016 in Series B. Four of its
pioneering CAR-T cell therapies, anti-GPC3 CAR-T for hepatocellular
carcinoma (HCC), anti-GPC3 CAR-T for squamous lung cancer (SLC),
cancer-specific anti-EGFR CAR-T for glioblastoma multiforme (GBM)
and first-in-class anti-Claudin18.2-CAR-T for gastric and
pancreatic cancer have all entered early clinical development. For
more information, please visit our website:
www.carsgen.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/carsgen-therapeutics-presented-at-the-2017-bio-international-convention-300478814.html
SOURCE CARsgen Therapeutics Co. Ltd.